Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes

Oz, Ozen; Kıyıcı, Sinem; Ersoy, Canan; Cander, Soner; Yorulmaz, Hakan; Gül, Cuma Bülent; Unal, Oguz Kaan; Sarandöl, Emre; Kırhan, Emine; Sığırlı, Deniz; Ertürk, Erdinç; Tuncel, Ercan; İmamoğlu, Şazi

doi:10.1016/j.diabres.2011.07.031

Cited by 12 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is definitely concluded that T2DM significantly contributes to loss of weight of the sufferers. Treating them with sitagliptin increases further the loss of weight as it is also mentioned by other researchers [16,17]. Similarly, T2DM decreases the second moments of area.…”

Section: Discussionsupporting

confidence: 67%

A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats

Kourkoulis

Pasiou

Abdi³

et al. 2019

Frattura Ed Integrità Strutturale

View full text Add to dashboard Cite

An experimental protocol is described aiming to explore the influence of Type 2 Diabetes Mellitus on the biomechanical response of the bone tissue and, also, to quantify the potential beneficial role of a pharmaceutical treatment, based on sitagliptin, a diabetes drug that increases the levels of natural substances called incretins. Twenty eight male, 10-week old Wistar rats were used, divided into three groups, i.e., the control one, the group including the diabetic rats and, finally, the group including the diabetic rats which were treated using sitagliptin. The biomechanical study was based on a series of three-point bending tests of the femora of the sacrificed rats and the analysis of the experimental data was implemented in terms of the actual geometry of the fractured cross-section. It was concluded that diabetic bones undertake larger forces despite the fact that the "diameter" of their crosssection was somehow smaller. On the contrary, the slope of the load-deflection curve (corresponding to a measure of the stiffness) of diabetic bones is slightly lower compared to the control bones. Finally, it seems that treating diabetic animals with sitagliptin only partly reverses the effect of Type 2 Diabetes Mellitus on their bone tissue, at least concerning its strength and stiffness.

show abstract

Section: Discussionsupporting

confidence: 67%

A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats

Kourkoulis

Pasiou

Abdi³

et al. 2019

Frattura Ed Integrità Strutturale

View full text Add to dashboard Cite

show abstract

“…In a study in Turkey (n = 28), sitagliptin 100 mg monotherapy for 12 weeks provided a reduction in HbA1c levels and body weight from baseline by 0.3% and 2.0 kg, respectively. In this study, HbA1c and BMI at baseline were 6.9 ± 0.7% and 31.6 ± 5.8 kg/m 2 , respectively [14]. The addition of sitagliptin (100 mg) to ongoing metformin therapy (n = 94) for 18 weeks decreased HbA1c and body weight by 0.73% and 0.4 kg, respectively, among patients in U.S.A. HbA1c and BMI at baseline were 7.8 ± 1.0% and 30.3 ± 4.7 kg/m 2 , respectively [15].…”

Section: Discussionmentioning

confidence: 87%

Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis

et al. 2012

View full text Add to dashboard Cite

BackgroundSitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Incretins stimulate insulin secretion from pancreatic β-cells and inhibit glucagon secretion from pancreatic α-cells, which is favorable for the treatment of diabetes. Sitagliptin is released on December, 2009, in Japan. We retrospectively studied effects of 6-month-treatment with sitagliptin on glucose and lipid metabolism, blood pressure, body weight and renal function in patients with type 2 diabetes by a chart-based analysis.MethodsWe retrospectively studied 220 type 2 diabetic patients who have taken sitagliptin for 6 months by a chart-based analysis. Subjects studied include patients treated with sitagliptin monotherapy, sitagliptin add-on therapy, and switching from glinide to sitagliptin. We selected patients who have both data before and after 6-month sitagliptin treatment and compared the data before the sitagliptin treatment with the data at 6 month after the sitagliptin treatment started. Body weight, blood pressure, plasma glucose, hemoglobin A1c (HbA1c), serum lipids, and estimated glomerular filtration rate in type 2 diabetic patients were measured almost at the same time points before and after 6-month-treatment with sitagliptin.ResultsBody weight was significantly reduced after 6-month sitagliptin treatment by 0.8 kg. HbA1c levels were also significantly decreased after the sitagliptin treatment by 0.6%. We found a significant and negative correlation between change in body weight and body mass index at baseline. We also observed a significant and negative correlation between change in HbA1c and HbA1c levels at baseline. The number of patients who showed the absence of urinary glucose was significantly increased after the sitagliptin treatment.

show abstract

“…These findings may be the reason for the increased plasma ghrelin levels observed at 30 min in miglitol and acarbose groups, but the mechanisms should be examined in more detail in the future. On the other hand, previous studies reported that the single administration of sitagliptin did not change postprandial total ghrelin levels in healthy subjects, and the administration of vildagliptin for 10 days did not change these levels in patients with T2DM [ 33 , 34 ]. These results are consistent with our own.…”

Section: Discussionmentioning

confidence: 99%

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study

et al. 2015

View full text Add to dashboard Cite

IntroductionBoth dipeptidyl peptidase-4 inhibitors and α-glucosidase inhibitors (α-GI) have been reported to change the incretin and insulin secretion. To examine the effects of acarbose, miglitol, and sitagliptin on glucose metabolism and secretion of gut peptides, we conducted a crossover study in patients with type 2 diabetes mellitus (T2DM).MethodsEleven Japanese patients with T2DM underwent four meal tolerance tests with single administration of acarbose, miglitol, sitagliptin, or nothing. Fasting and postprandial plasma levels of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured.ResultsEarly-phase insulin secretion was reduced following acarbose and miglitol, and the areas under the curve (AUC) of insulin at 180 min following acarbose and miglitol were significantly lower than sitagliptin. AUC of plasma glucose at 180 min after acarbose, miglitol, and sitagliptin tended to be lower than in controls, and plasma glucose levels at 30–60 min following miglitol were significantly lower than in controls. Plasma glucagon, ghrelin, and des-acyl ghrelin levels did not differ among the four conditions. Postprandial plasma active GLP-1 levels and AUC of GLP-1 increased significantly in both the sitagliptin and miglitol groups compared to control. Postprandial plasma total GIP levels increased following sitagliptin but decreased after acarbose and miglitol. Changes in incretin levels tended to be greater with miglitol than acarbose.ConclusionThese results showed that sitagliptin and α-GIs, miglitol more so than acarbose, improved hyperglycemia in patients with T2DM after single administration, and had different effects on insulin and incretin secretion.Trial registration: UMIN-CTR number, UMIN000009981.Electronic supplementary materialThe online version of this article (doi:10.1007/s13300-015-0113-3) contains supplementary material, which is available to authorized users.

show abstract

Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes

Cited by 12 publications

References 22 publications

A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats

A biomechanical study of the role of sitagliptin on the bone characteristics of diabetic rats

Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis

Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study

Contact Info

Product

Resources

About